SYMTUZA® has been proven to help patients reach and maintain undetectable, whether new to treatment or switching to SYMTUZA®.
SYMTUZA® contains darunavir, which can help reduce your risk of drug resistance and maintain an undetectable viral load.
Studies have shown that SYMTUZA® is both tolerable and effective for those new to treatment or switching to SYMTUZA®.
There can be many challenges to starting and staying on treatment. Once you and your healthcare provider have decided that SYMTUZA® is right for you, Janssen CarePath will help you find the resources you may need to get started and stay on track.